---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-087408"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:27:21.597972+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Invivyd announces PEMGARDA commercial launch, 2024 revenue guidance $150M-$200M

## Summary
- PEMGARDA now commercially available in the U.S. for COVID-19 PrEP in immunocompromised adults/adolescents.
- 2024 net product revenue guidance of $150M to $200M.
- Expects to end 2024 with at least $55M in cash and cash equivalents.
- Received FDA EUA on March 22, 2024; product available for order within two weeks.

## SEC filing metadata
- accession: 0001193125-24-087408
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524087408/0001193125-24-087408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524087408/d818209d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-087408
- JSON: https://secwatch.observer/filing/0001193125-24-087408.json
- Plain text: https://secwatch.observer/filing/0001193125-24-087408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.